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The accelerated metabolism of tumor cells, inevitable for maintaining high proliferation
rates, is an emerging target for tumor therapy. Increased glucose and lipid metabolism
as well as mitochondrial activity have been shown in solid tumors but also in leukemic
cells. As tumor cells are able to escape the blockade of one metabolic pathway
by a compensatory increase in other pathways, treatment strategies simultaneously
targeting metabolism at different sites are currently developed. However, the number of
clinically applicable anti-metabolic drugs is still limited. Here, we analyzed the impact
of the anti-diabetic drug metformin alone or in combination with two non-steroidal
anti-inflammatory drugs (NSAIDs) diclofenac and diflunisal on acute myeloid leukemia
(AML) cell lines and primary patient blasts. Diclofenac but not diflunisal reduced lactate
secretion in different AML cell lines (THP-1, U937, and KG-1) and both drugs increased
respiration at low concentrations. Despite these metabolic effects, both NSAIDs showed
a limited effect on tumor cell proliferation and viability up to a concentration of
0.2 mM. In higher concentrations of 0.4–0.8 mM diflunisal alone exerted a clear
effect on proliferation of AML cell lines and blocked respiration. Single treatment with
the anti-diabetic drug metformin blocked mitochondrial respiration, but proliferation
and viability were not affected. However, combining all three drugs exerted a strong
cytostatic and cytotoxic effect on THP-1 cells. Comparable to the results obtained
with THP-1 cells, the combination of all three drugs significantly reduced proliferation
of primary leukemic blasts and induced apoptosis. Furthermore, NSAIDs supported
the effect of low dose chemotherapy with cytarabine and reduced proliferation of
primary AML blasts. Taken together we show that low concentrations of metformin and
the two NSAIDs diclofenac and diflunisal exert a synergistic inhibitory effect on AML
proliferation and induce apoptosis most likely by blocking tumor cell metabolism. Our
results underline the feasibility of applying anti-metabolic drugs for AML therapy.
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INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous group
of neoplastic disorders characterized by the accumulation of
myeloid blasts in the bone marrow and blood as well as an
arrest in differentiation. AML represents the most common acute
leukemia in adults and is still a mostly incurable and lethal disease
in the majority of patients. Induction therapy with cytarabine and
anthracyclines is highly effective in killing leukemic cells and has
largely remained unchanged since the 1970s (Perl, 2018). Despite
a high rate of complete remissions, the overall survival is very
poor as many patients relapse. Relapses are caused by regrowth
of chemotherapy-resistant leukemic cells.
New studies expanded the knowledge on AML heterogeneity
and identified new molecular groups. These advances are
now translated into several new targeted therapies (Perl,
2017). Mutations in isocitrate dehydrogenase (IDH)1 or
IDH2 are detected in approximately 15% of AML patients.
Both enzymes are important for cell energy metabolism and
catalyze the interconversion of isocitrate into α-ketoglutarate.
AML therapy with oral, small-molecule inhibitors of mutant
IDH1 and mutant IDH2, respectively, has shown promising
results (Stein et al., 2017; DiNardo et al., 2018) indicating
that metabolic targeting is an effective approach for AML
therapy.
In solid tumors it is well-established that oncogenes
reprogram tumor metabolism and accelerate glucose metabolism.
This phenomenon, known as the “Warburg effect,” is associated
with an aggressive phenotype and poor prognosis in many tumor
entities (Renner et al., 2017). Ju et al. (2017) described that
internal tandem duplication (ITD) mutation in fms like tyrosine
kinase (FLT) 3 (FLT3/ITD), which is detected in about 30% of
AML patients, promotes the Warburg effect. Leukemia cell lines
overexpressing FLT3/ITD exhibited increased glucose uptake and
lactate secretion. In line, the commonly used glycolytic inhibitor
2-deoxyglucose (2-DG) potentiated the anti-leukemia effect of
sorafenib. These data suggest that combination of metabolic
intervention and conventional chemotherapy could be exploited
as therapeutic strategy in patients with FLT3/ITD mutation (Ju
et al., 2017).
In line, inhibition of glycolytic metabolism by 2-DG increased
the efficacy of Aurora kinase inhibitors in AML cell lines (Liu
et al., 2013) and potentiated the cytotoxicity of arabinofuranosyl
cytidine (Chen et al., 2014).
Many hypotheses tried to explain the therapeutic resistance
in AML patients. A linkage between reduced sensitivity to
chemotherapy and accelerated glycolysis has been described
in a murine AML model. Here, chemotherapy-resistant AML
exhibited increased lactate production and fewer mitochondria
(Nobrega-Pereira et al., 2018). In contrast, another study
demonstrated that cytarabine-resistant cells displayed a shift to
fatty acid oxidation and increased oxidative phosphorylation
(OXPHOS) (Farge et al., 2017). Similar results were obtained by
Qian et al. (2016) showing that high expression of TP53-induced
glycolysis and apoptosis regulator (TIGAR), which inhibits
glycolysis, was associated with poor survival and high incidence
of relapse. Furthermore, Gallipoli et al. (2018) showed that
FLT3/ITD AML depends on glutaminolysis which supports
mitochondrial activity.
Vascular endothelial growth factor (VEGF)-signaling seems to
be associated with changes in metabolism and chemoresistance.
Blocking VEGF receptor 2 (VEGFR2) induced mitochondrial
biogenesis and increased the vulnerability of leukemic cells
(Nobrega-Pereira et al., 2018). VEGF-C induces cyclooxygenase
(COX)-2 expression in AML cell lines and COX-2 inhibition
limits tumor cell proliferation in vitro and suppresses xenograft
tumor formation (Zhang et al., 2013; Hua et al., 2014). Moreover,
combination of celecoxib, a COX-2 inhibitor, with doxorubicin
revealed a synergistic effect on growth inhibition and apoptosis
induction in the AML cell line HL-60 and primary AML cells
(Chen et al., 2013).
These results suggest that AML cells are heterogeneous in
their metabolic profile and use different metabolic pathways
to fuel proliferation and acquire resistance to chemotherapy.
Here we investigated the impact of three inhibitors which target
glycolysis, COX, and OXPHOS alone and in combination on
AML cell lines and primary human AML blasts. Our study
illustrates that simultaneous targeting of different metabolic
pathways may represents a powerful therapeutic strategy for
AML patients.
MATERIALS AND METHODS
Chemicals and Drugs
All drugs were purchased from Sigma-Aldrich (St Louis, MO,
United States) and dissolved in water, unless otherwise indicated.
The sodium salt of diclofenac (Fagron, Barsbüttel, Germany)
and metformin hydrochloride (Sigma-Aldrich) were dissolved
in culture medium. Diflunisal (Fluka, Munich, Germany) was
dissolved in 20 mM arginine containing water and cytarabine
(Stada, Bad Vilbel, Germany) in 0.11 mM sodium lactate
solution.
Cells and Cell Culture
The cell lines U937 (human histiocytic leukemia, DSMZ)
and THP-1 (monocytic leukemia cell line, DSMZ) were
cultured in RPMI 1640, 10% fetal calf serum (both from PAN
Biotech, Aidenbach, Germany), 2 mM glutamine, 50 U/mL
penicillin/50 µg/mL streptomycin (all from Gibco/Life
Technologies, Carlsbad, CA, United States) at 5% CO2 and
37◦C.
Primary AML blasts were obtained from patients after
written informed consent. The study was approved by the
Institutional Ethics Committee of the University Hospital of
Regensburg and designed and conducted in accordance with
the Declaration of Helsinki (ethic vote 05-097). AML blasts
were cultured in RPMI 1640, 10% fetal calf serum (both from
PAN), 10% human AB serum, 2 mM glutamine, 50 U/mL
penicillin/50 µg/mL streptomycin (all from Gibco), 20 ng/mL
IL-3, G-CSF as well as TPO (all from Peprotech, Hamburg,
Germany). 5 × 105 cells/mL medium were seeded in 24-well
plates at 5% CO2 and 37◦C. Every 3–4 days, medium was
changed.
Frontiers in Pharmacology | www.frontiersin.org 2 November 2018 | Volume 9 | Article 1258
fphar-09-01258 October 31, 2018 Time: 16:24 # 3
Renner et al. Combined Metabolic Targeting of AML
Determination of Cell Proliferation
To measure proliferation of cell lines, 3 × 104 cells/0.2 mL
medium were seeded into flat-bottom 96-well plates with
indicated concentrations of diclofenac, diflunisal, metformin
and cytarabine. To analyze immediate anti-proliferative
effects, 0.5 µCi/0.2 mL 3H-thymidine (Amersham Pharmacia,
Piscataway, NJ, United States) was added after 2 h and
3H-thymidine incorporation was determined after 24 h. In a
second set of experiments, cells were labeled after 24 h and
cultured for another after 24 h (48 h total).
Determination of Apoptosis
For analysis of apoptosis, 3–5 × 105 cells/mL medium
were treated with diclofenac, diflunisal, metformin and
cytarabine for 24 h or 48 h. After treatment, cells were
stained with Annexin-V-FITC and 7-aminoactinomycin D
(7-AAD) (both from BD Biosciences, Franklin Lakes, NJ,
United States) according to the manufacturer’s instructions.
Flow cytometric analyses were performed on a FACSCalibur
(BD Biosciences) using BD CellQuestPro for data acquisition
and analysis. Final processing and analysis was performed
with FlowJo v9.5.3 software (FlowJo,LLC, Ashland, OR,
United States).
Determination of Lactate in Tumor Cell
Supernatants
Cells were seeded into 24-well plates at a concentration of
5 × 105 cells/ mL medium with or without diclofenac, diflunisal,
metformin and cytarabine. After 24 or 48 h, lactate levels in
cell culture supernatants were determined with a Dimension
Vista (Siemens, Munich, Germany) using reagents from Roche
(Mannheim, Germany) at the Department of Clinical Chemistry,
University Clinic, Regensburg, Germany.
Online-Measurement of Oxygen
Concentration in Cell Culture
The SDR SensorDish R© Reader (PreSens Precision Sensing
GmbH, Regensburg, Germany) is a 24-channel oxygen
and pH meter. The optical oxygen (OxoDish R©) sensor is
integrated at the bottom of each well of a 24-well multidish.
The sensors are luminescent dyes embedded in an analyte-
sensitive polymer. The luminescence lifetime of these dyes
depends on the amount of analyte. The sensors are read
out non-invasively through the bottom of the multidish by
the SensorDish R© Reader. The resulting signal is converted
automatically to the respective parameter (dissolved oxygen)
using calibration parameters stored in the software. 5 × 105
cells/mL medium were incubated with or without diclofenac,
diflunisal, metformin and cytarabine. The SensorDish R© Reader
was used in the incubator for the whole duration of the 16-h
cultivation period and measurements were performed in 30–60 s
intervals.
Statistical Analysis
All results represent mean ± standard error (SEM) of at
least three independent experiments. Significance was
determined by ANOVA and post hoc by Holm-Sidak’s
multiple comparisons test, ∗∗∗p < 0.001; ∗∗p < 0.01; and
∗p< 0.05.
RESULTS
Tumor metabolism supports tumor growth and is associated
with chemotherapy resistance. Targeting tumor metabolism is an
attractive option to support conventional tumor therapy. Here
we investigated the impact of anti-metabolic drugs alone or
in combination on human AML cell lines and primary AML
blasts.
Impact of Metformin, NSAIDs and 2-DG
on Metabolism and Proliferation of AML
Cell Lines
The anti-diabetic drug metformin lowers OXPHOS via inhibiting
complex I of the electron transport chain in the mitochondria.
Several studies addressed the anti-cancer potential of metformin
in vitro and in clinical trials, however, mainly in solid tumors
(Pollak, 2014). Metformin accelerated glucose metabolism and
increased lactate secretion in the human AML cell line THP-1
starting from concentrations of 1 mM (Figure 1A). In parallel,
oxygen consumption was blocked (Figure 1B). Diclofenac,
a non-steroidal anti-inflammatory drug (NSAID) which has
been shown to inhibit glucose metabolism (Gottfried et al.,
2013) significantly decreased lactate secretion starting from
0.05 mM and increased oxygen consumption (Figures 1C,D).
Another NSAID, diflunisal, exhibited no effect on lactate
secretion but increased oxygen consumption in concentrations
of 0.1–0.2 mM (Figures 1E,F). However, at higher diflunisal
concentrations of 0.4–0.8 mM, OXPHOS was inhibited
(Figure 1F). In comparison, we tested a classical glycolytic
inhibitor, 2-deoxyglucose (2-DG). A decrease in lactate secretion
was obtained with high 2-DG concentrations of 1–10 mM
(Figure 1G); OXPHOS inhibition occurred at 10 mM 2-DG
(Figure 1H).
Next we analyzed whether metabolic targeting modulates cell
growth of different AML cell lines. Even though metformin
significantly blocked respiration at doses of 1-10 mM, no
significant effect on proliferation was detected for THP-1, U937,
and KG-1 AML cell lines (Figures 2A–C). This could in part
be because decreased OXPHOS was compensated by increased
glycolytic activity as shown by increased lactate secretion
after metformin treatment (Figure 1A). Proliferation was not
significantly lowered by diclofenac in THP-1 cells (Figure 2D)
whereas U937 and KG-1 were more susceptible to diclofenac
treatment resulting in decreased proliferation (Figures 2E,F).
Diflunisal significantly inhibited proliferation in all three AML
cell lines (Figures 2G–I) starting from a concentration of
0.4 mM where OXPHOS was clearly blocked. In contrast
to metformin, AML cells treated with diflunisal showed no
compensation regarding glycolytic activity as lactate production
was not altered after diflunisal treatment. (Figure 1E). 2-DG
also inhibited proliferation at concentrations of 10 mM where
both OXPHOS and glycolysis was blocked (Figures 2J–L). These
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FIGURE 1 | Metabolic effects of single treatment with metformin, diclofenac,
diflunisal and 2-DG on THP-1 cells. (A,C,E,G) Cells were seeded in 24-well
plates at a concentration of 5 × 105 cells/ mL medium with or without
metformin, diclofenac, diflunisal and 2-DG in the indicated concentrations.
After 24 h, cumulative lactate levels in cell culture supernatants were
determined. (B,D,F,H) Cells were seeded in the same density in 24-well
dishes with integrated optical oxygen (OxoDish R©) sensors in the bottom of
each well. The SensorDish R© Reader was placed in the incubator for 24 h and
measurements were performed in 30–60 s intervals. (A,C,E,G) data are
shown as mean ± SEM (n ≥ 3), ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001
significance was calculated by ANOVA and post hoc Holm-Sidak’s multiple
comparisons test. (B,D,F,H) data are shown as mean (n ≥ 3 with the
exception of (F) 0.4–0.8 mM diflunisal n = 2).
data indicate that metabolic targeting only results in robust
proliferation arrest when glycolysis and OXPHOS are targeted
simultaneously.
Combined Metabolic Targeting Limits
Proliferation of Leukemia Cell Lines and
Primary Blasts
Next we tried to combine low physiological doses of the
drugs to augment the effect compared to the single treatment.
Combination of 0.1 mM of diclofenac and 0.1 mM diflunisal,
clearly suppressed the proliferation of U937 but not in THP-1
and primary AML blasts (Figures 3A–C). Addition of 1 mM
metformin, which as a single drug had no impact on proliferation,
could overcome the resistance of THP-1 against NSAIDs and the
combined treatment significantly lowered the proliferation rate
of THP-1 cells but not primary AML blasts (Figures 3B,C).
As the salicylic acid derivative diflunisal can be administered
to patients in 10-fold higher concentrations compared to
diclofenac, we increased the diflunisal dose and combined it with
low concentrations of diclofenac and metformin (Figures 3D–I).
As shown in Figure 2G, diflunisal alone inhibited THP-1
proliferation at a concentration of 0.4–0.8 mM. Combined
treatment with diclofenac and metformin could not further
decrease the proliferation rate of THP-1 cells (Figures 3D,G).
In primary AML blasts no significant effect was detected
with diflunisal plus diclofenac (Figure 3E) after 24 h, but
addition of metformin reduced proliferation (Figure 3H).
When we prolonged the treatment to 48 h, this effect was
even more pronounced and also 0.4 mM diflunisal as triple
combination therapy significantly reduced proliferation of
primary blasts (Figure 3I). For direct comparison we normalized
the proliferation under single drug treatment and the various
combinations to untreated cells (Figures 3J–L). Taken together,
these data prove that combination of two or three treatments
which alone were not effective resulted in cytostatic effects not
only in cell lines but also primary blasts.
Metabolic Effects of NSAIDs and
Metformin on Primary AML Blasts
Analysis of the metabolic effects of the drugs on AML
blasts revealed similar results compared to the leukemia
cell lines. Metformin accelerated lactate secretion whereas
diclofenac alone or in combination with diflunisal reduced
lactate secretion (Figures 4A,B). Combination of all three drugs
resulted in a slightly reduced lactate secretion even though
metformin alone doubled the lactate secretion (Figures 4A,C).
Furthermore, oxygen consumption was determined with the
Presens technology. In contrast to THP-1 cells (Figure 1F),
diflunisal increased oxygen consumption in primary blasts even
in high diflunisal concentrations of 0.8 mM (Figure 4D).
Diclofenac alone or in combination with 0.1 mM diflunisal had
no effect on oxygen consumption (Figures 4D,E). Metformin
again inhibited respiration alone and in combination with the
NSAIDs (Figures 4D,F) thereby counteracting the effect of
diflunisal on OXPHOS.
Apoptosis Induction by Combined
Metabolic Targeting
To distinguish proliferation arrest from the induction of
cell death, we incubated THP-1 cells with the drugs alone
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FIGURE 2 | Cytostatic effects of single treatment with metformin, diclofenac, diflunisal and 2-DG on the proliferation of myeloid leukemic cell lines. To analyze effects
on proliferation of (A,D,G,J) THP-1, (B,E,H,K) U937 and (C,F,I,L) KG-1, 3 × 104 cells/0.2 mL medium were seeded in 96-well plates with indicated concentrations
of metformin, diclofenac, diflunisal and 2-DG. 3H-thymidine was added after 2 h and 3H-thymidine incorporation was determined after 20–22 h. (A–K) data are
shown as mean ± SEM (n ≥ 4), ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 significance was calculated by ANOVA and post hoc Holm-Sidak’s multiple comparisons
test. L data are shown as mean (n = 2).
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FIGURE 3 | Cytostatic effects after combined treatment with metformin, diclofenac and diflunisal on AML cells. 3 × 104cells/0.2 mL medium (A) U937 cells or
(B) THP-1 cells or (C) primary blasts were seeded in 96-well plates with 1 mM metformin, 0.1 mM diclofenac and 0.1 mM diflunisal alone or in the indicated
combinations. 3H-thymidine incorporation was determined after 24 h. In a second set of experiments we increased the diflunisal concentration. (D) THP-1 cells or
(E) primary blasts were incubated with 0.1 mM up to 0.8 mM diflunisal plus low dose 0.1 mM diclofenac for 24 h. (F) alternatively, the incubation period of primary
blasts was prolonged to 48 h. (G–I) in another set of experiments the triple combination with diclofenac and 1 mM metformin was used. Proliferation under single
drug treatment or the various drug combinations was normalized to respective controls and is shown for (J) THP-1 cells and primary blasts treated for (K) 24 h or (L)
48 h. data are shown as mean ± SEM (n ≥ 3), ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 significance was calculated by ANOVA and post hoc Holm-Sidak’s multiple
comparisons test.
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FIGURE 4 | Metabolic effects of treatment with metformin, diclofenac and diflunisal on primary blasts. AML blasts were seeded in 24-well plates at a concentration
of 5 × 105 cells/mL medium with or without metformin, diclofenac and diflunisal and 2-DG in the indicated concentrations. (A–C) After 24 h, cumulative lactate levels
in cell culture supernatants were determined. (D–F) Cells were seeded in the same density in 24-well dishes with integrated optical oxygen (OxoDish R©) sensors in
the bottom of each well. The SensorDish R© Reader was placed in the incubator for 24 h and measurements were performed in 30–60 s intervals. A,D show single
treatments; in B,E diflunisal was combined with 0.1 mM diclofenac and in C,F triple treatments of diflunisal, diclofenac and metformin are shown. (A–C) data are
shown as mean ± SEM (n ≥ 3), ∗P < 0.05 and ∗∗P < 0.01; significance was calculated by ANOVA and post hoc Holm-Sidak’s multiple comparisons test. (D–F)
data are shown as mean (n = 3).
and in combination and stained with annexin-V/7-AAD to
determine apoptosis. Low concentrations of diclofenac but not
diflunisal and metformin induced apoptosis, however, high
diflunisal concentration of 0.8 mM had a strong effect on cell
viability (Figure 5A). The combination of low concentrations
of diclofenac and diflunisal induced apoptosis (Figure 5B).
Metformin had no effect and could not further support the
effect of diclofenac and diflunisal (Figure 5C). Morphology and
original flow cytometry data presented either as scatter blots or
histograms of Annexin-V/7-AAD staining of THP-1 cells under
treatment are shown in Figures 5D–F. Percentage of Annexin-
V single positive cells (lower right quadrant), regarded as early
apoptotic cells, 7-AAD single positive cells (upper left quadrant),
regarded as necrotic cells or Annexin V/7-AAD double positive
cells (upper right quadrant), representing late apoptotic cells,
can be depicted either from scatter blots or histograms
(Figures 5D–F).
In contrast to THP-1 cells, AML blasts did not respond to
single drug treatment (Figure 6A). Combination of low doses
of diclofenac with high concentrations of 0.8 mM diflunisal
also had no effect (Figure 6B). Applying 0.8 mM diflunisal as
triple therapy together with diclofenac and metformin resulted
in apoptosis induction (Figures 6C–E). This effect is also clearly
visible from the pictures, FCS/SSC characteristics and original
data on Annexin-V/7-AAD staining, presented either as scatter
blots or as histograms (Figures 6D–F).
Metabolic Targeting in Combination With
Metronomic Chemotherapy
Finally, we analyzed the impact of low dose standard
chemotherapy with cytarabine alone and in combination
with anti-metabolic treatment. In THP-1 cells and in primary
blasts, cytarabine dose-dependently inhibited proliferation and
the effect of cytarabine was more pronounced in primary blasts
(Figures 7A,B). Triple combination of diclofenac, diflunisal and
low dose cytarabine almost completely shut down proliferation
of primary blasts and THP-1 cells (Figures 7A,B). However,
low dose 0.02 and 0.1 µM cytarabine had little impact on
apoptosis induction compared to untreated cells (data not
shown and Figures 7C–F). Combination of low dose 0.1 µM
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FIGURE 5 | Impact of metformin, diclofenac and diflunisal on apoptosis in THP-1 cells. For analysis of apoptosis, 3–5 × 105 cells/mL medium were treated with (A)
single drugs or (B) combination of increasing concentrations of diflunisal (0.1–0.8 mM) plus 0.1 mM diclofenac or (C,E) triple combinations for 48 h. After treatment,
pictures were taken to document the morphology of (D) untreated or (E) treated cells; one representative experiment is shown. Cells were stained for Annexin-V-FITC
and 7-aminoactinomycin D (7-AAD) and analyzed by flow cytometry. Percentage of Annexin-V single positive cells (lower right quadrant), regarded as early apoptotic
cells, 7-AAD single positive cells (upper left quadrant), regarded as necrotic cells or Annexin V/7-AAD double positive cells (upper right quadrant), representing late
apoptotic cells, can be depicted either from scatter blots or histograms (D,E) Representative scatter blots and (F) histograms are presented. (A–C) data are shown
as mean ± SEM (n = 3), ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001; significance was calculated by ANOVA and post hoc Holm-Sidak’s multiple comparisons test.
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FIGURE 6 | Impact of metformin, diclofenac and diflunisal on apoptosis in primary AML blasts. For analysis of apoptosis, 3–5 × 105 cells/mL medium were treated
with (A) single drugs or (B) combination of diflunisal (0.4 mM, 0.8 mM) plus 0.1 mM diclofenac or (C,E) triple combinations for 48 h. After treatment, pictures were
taken to document the morphology of (D) untreated or (E) treated cells; one representative experiment is shown. Then AML blasts were stained with Annexin-V-FITC
and 7-aminoactinomycin D (7-AAD) and analyzed by flow cytometry. Percentage of Annexin-V single positive cells (lower right quadrant), regarded as early apoptotic
cells, 7-AAD single positive cells (upper left quadrant), regarded as necrotic cells or Annexin V/7-AAD double positive cells (upper right quadrant), representing late
apoptotic cells, can be depicted either from scatter blots or histograms (D,E) Representative scatter blots and (F) histograms are presented. (A–C) data are shown
as mean ± SEM (n = 3), ∗P < 0.05; significance was calculated by ANOVA and post hoc Holm-Sidak’s multiple comparisons test.
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FIGURE 7 | Impact of cytarabine in combination with diclofenac and diflunisal on proliferation and apoptosis in AML cells. To analyze effects on proliferation of
(A) THP-1 or (B) primary blasts 3 × 104 cells/0.2 mL medium were seeded in 96-well plates with indicated concentrations of cytarabine, diclofenac and diflunisal.
3H-thymidine was added after 24 h and 3H-thymidine incorporation determined after another 24 h. For analysis of apoptosis, 3–5 × 105 cells/mL medium were
treated with or without cytarabine as a (C–F) single drug or (G,H) triple combination of cytarabine with diflunisal and diclofenac for 48 h. Cells were stained with
Annexin-V-FITC and 7-aminoactinomycin D (7-AAD) and analyzed by flow cytometry. (A,B) Data are shown as mean ± SEM (two independent experiments in
triplicate for THP-1, one experiment in triplicate for AML blasts). (C–H) Apoptosis was analyzed in one experiment with either THP-1 or primary blasts.
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cytarabine with diclofenac and diflunisal could induce apoptosis
in THP-1 cells and a limited effect was observed for primary
blasts (Figures 7G,H).
DISCUSSION
Cellular proliferation requires nutrient uptake, synthesis of
building blocks and energy. Oncogenes that drive tumor cell
proliferation directly or indirectly lead to metabolic changes;
c-MYC and other oncogenes upregulate metabolite transporters
and enzymes required for glucose metabolism (Vander Heiden
and DeBerardinis, 2017). In line, the majority of tumor cells
are characterized by an accelerated glucose metabolism and
metabolize pyruvate into lactate even in the presence of adequate
oxygen, a phenomenon known as “Warburg effect” (Warburg
et al., 1927). Glycolysis generates building blocks to guarantee
rapid tumor growth whereas OXPHOS provides energy.
Many classical anticancer agents inhibit nucleotide
metabolism, but some chemotherapeutic drugs have also been
shown to target tumor energy metabolism. Cyclophosphamide
caused a drop in the glycolytic rate in a murine fibrosarcoma
model (Poptani et al., 2003). Sorafenib, a multikinase inhibitor,
has been shown to limit mitochondrial activity and resistance
was associated with glycolytic reprogramming (Tesori et al.,
2015). Therefore, metabolic changes occur in tumors during
chemotherapy and seem to relate to the development of
resistance.
Here, we analyzed the efficacy of drugs targeting glycolysis,
COX, and OXPHOS alone and in combination on AML cell lines
and primary human AML blasts.
Our data show that the glycolytic inhibitor 2-DG and low
concentrations of the NSAID diclofenac both limit glycolysis and
decrease lactate secretion of AML cell lines. Furthermore, both
drugs modulated respiration; in low concentration diclofenac and
diflunisal increased respiration. However, higher concentrations
of diflunisal and 2-DG decreased oxygen consumption. In line,
several other NSAIDs impair mitochondrial activity indicating
that OXPHOS inhibition is a COX-related effect (Moreno-
Sanchez et al., 1999). But the inhibition of lactate secretion
by diclofenac seems not to be related to COX inhibition since
diflunisal, another NSAID, had no effect on lactate production. In
line, it has been shown that even high concentrations of aspirin
have no effect on lactate secretion in melanoma cells (Gottfried
et al., 2013). One possible explanation is that diclofenac directly
targets the lactate transporter MCT4 which has been suggested
by Sasaki et al. in colon carcinoma cells (Sasaki et al., 2016).
Furthermore, an inhibitory effect of diclofenac on the uptake of
lactic acid has been demonstrated by Emoto et al. (2002).
The glycolytic inhibitor 2-DG has already been tested in
clinical trials with limited efficacy. Raez et al. (2013) investigated
the maximum tolerated dose of 2-DG in combination with
docetaxel and achieved median 2-DG plasma concentrations
of 116 ug/ml (about 0.7 mM) in patients with advanced solid
tumors. As most in vitro studies use concentrations above 1 mM
2-DG, this indicates that effective 2-DG concentrations will most
likely not be reached in patients. Therefore novel compounds that
can target glycolysis in patients are warranted. In our experiments
0.1 mM diclofenac was even more effective than 10 mM 2-DG in
decreasing lactate secretion, a concentration which is achievable
in patients (Drugs.com, 2018). Based on these data, we conclude
that the described inhibitory effects of diclofenac on tumor cells
in vitro and in murine tumor models may in part relate not only
to COX inhibition but also to glycolysis inhibition (Pantziarka
et al., 2016).
Diflunisal is a difluorophenyl derivative of salicylic acid
which has been shown to be an effective and well-tolerated
analgesic for long-term use. In contrast to diclofenac it has a
long half-life and prolonged intake of 500 mg b.i.d. for 11 days
results in mean peak plasma levels of 190 ± 33 µg/mL (about
0.8 mM, Drugs.com, 2018). In our hands high concentrations
of 0.8 mM diflunisal alone could inhibit proliferation of AML
cell lines and primary blasts but induction of apoptosis was
only achieved in combination with low dose diclofenac and
metformin. Recently it has been shown that diflunisal can
inhibit the growth of AML1-ETO positive leukemia cells in
SCID mice via specific inhibition of CBP/p300 acetyl-transferase
activity. Competition of diflunisal with acetyl-CoA at the
catalytic side blocks acetylation of histones and non-histone
proteins (Shirakawa et al., 2016). CBP/p300 also acetylates
transcriptional regulators such as c-MYC and acetylation
decreases ubiquitination, which results in stabilization of c-MYC
proteins (Vervoorts et al., 2003). These findings suggest a possible
link between c-MYC destabilization by diflunisal and its impact
on tumor proliferation as c-MYC directly regulates glucose
metabolic enzymes as well as genes involved in mitochondrial
biogenesis (Gao et al., 2009). Beside these non-classical effects
of diflunisal, it could probably also reduce AML proliferation
via COX-2 inhibition as several reports show that COX-2
inhibition limits leukemia growth (Zhang et al., 2013; Hua et al.,
2014).
Metformin is commonly used for the treatment of type
2 diabetes and epidemiological studies indicate that tumor
incidence is lower in diabetic patients taking metformin
(Heckman-Stoddard et al., 2017). In the acute pro-myelocytic
leukemia (APL) cell line NB4 metformin has been shown to
induce degradation of c-Myc and to induce apoptosis, however,
only at concentrations of 5 mM and higher (Huai et al., 2012).
In another APL cell line HL-60 low metformin concentrations of
0.4 mM in combination with paclitaxel could induce apoptosis
(Asik et al., 2018). In our experiments metformin alone had
neither an effect on tumor cell proliferation nor on apoptosis
even at concentrations up to 10 mM but OXPHOS activity was
clearly suppressed in AML cell lines and primary blasts. This
indicates that metformin reprograms tumor cell metabolism and
shifts energy production to glycolysis. In line, lactate secretion
was enhanced by metformin treatment. This may explain the
synergistic anti-proliferative effect of diclofenac and metformin
as diclofenac lowers the glycolytic activity.
Targeting OXPHOS has also been suggested by Farge
et al. (2017) for chemotherapy-resistant AML cells. Here,
cytarabine-resistant AML cells exhibited a specific metabolic
phenotype characterized by high OXPHOS. Targeting OXPHOS
with 10 mM metformin enhanced the antileukemic effects of
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2 µM cytarabine. We combined low dose 0.02 µM cytarabine,
the most effective cytostatic drug used in the treatment of AML
patients, with metformin and NSAIDs. Cytarabine as a single
drug exhibited clear effects on proliferation of leukemia cell
lines and primary AML blasts, however, the impact on apoptosis
induction was limited. Combination with NSAIDs clearly
accelerated apoptosis induction suggesting that combination of
low dose chemotherapy with metabolic targeting is an effective
strategy.
In summary, there is increasing evidence that not only
solid tumors but also leukemia, exhibit changes in metabolism
which could be used for metabolic targeting. Beside AMLs with
increased glycolytic activity (Ju et al., 2017) other reports state
that OXPHOS is of specific importance for AML cells (Farge
et al., 2017). These data suggest a broad heterogeneity in oxidative
and metabolic requirements in AML cells. Therefore, induction
of anakoinosis with combined metabolic targeting of glycolysis,
COX and mitochondrial activity together with low dose standard
chemotherapy might present a promising therapeutic strategy in
AML.
CONCLUSION
This study has shown that anti-metabolic treatment can be used
to inhibit AML cell line and primary blast proliferation and
induce apoptosis in physiologically achievable concentrations.
These findings suggest that targeting tumor cell metabolism is
an option not only for solid tumors but also hematological
malignancies.
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